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Background
Soluble guanylate cyclase (sGC) is a heterodimer, consist-
ing of an alpha1- or alpha2-subunit and a beta1-subunit.
Activation of sGC by NO/CO critically depends on the
presence of a prosthetic ferrous heme group, linked to the
axial ligand His-105 of the beta1-subunit. Removal of this
heme moiety as well as its oxidation abolishes any NO-
induced enzyme activation. To differentiate between sGC-
dependent and sGC-independent functions of NO, and to
differentiate between heme-dependent and heme-inde-
pendent functions of sGC, we generated heme-deficient
sGCbeta1H105F knockin (KI) mice, in which sGC retains its
basal activity, but can no longer be activated by NO.
Methods
sGCbeta1H105F knockin mice were generated using a clas-
sical approach by which the sGCbeta1 allele was replaced
with a mutated allele by means of homologous recombi-
nation. As such, the codon for the His-105 residue of the
sGCbeta1-subunit was replaced by a codon for Phe. Ini-
tially, mice were phenotyped on a mixed background of
129S6xC57Bl/6J. Non-invasive basal systolic blood pres-
sure (SBP) and heart rate (HR) measurements were per-
formed in male and female wild-type (WT) and
sGCbeta1H105F  knockin mice with a tail-cuff pressure-
recording device (Visitech BP-2000/Hatteras MC4000)
and with telemetry in free living animals (DSI).
Results
sGCbeta1H105F knockin mice showed a reduced life span,
gastro-intestinal tract abnormalities and growth retarda-
tion. Basal SBP was higher in sGCbeta1H105F knockin mice
than in WT mice, while HR was lower in sGCbeta1H105F
knockin compared to their WT littermates. Moreover the
blood pressure response to NO-donors (DETA-NO, SNP)
and L-NAME was abolished, while the action of the heme-
independent sGC activator Bay 58-2667 was preserved.
Relaxation of precontracted aortic rings with NO-donors
was completely impaired and in addition the concentra-
tion-response curve after the heme-dependent stimulator
Bay 41-22172 strongly shifted to the right in KIKI aorta's
vs. WT (IC50 830 nM vs 34 nM). In contrary the curve
after Bay 58-2667 shifted to the left (IC50 0.26 nM vs 1.23
nM). This corroborates the hypothesis that Bay 58-2667
preferably activates the heme-free form of sGC both in
vitro and in vivo.
Conclusion
The NO-activated state of sGC is necessary for the normal
function of a number of important physiological proc-
from 4th International Conference of cGMP Generators, Effectors and Therapeutic Implications
Regensburg, Germany. 19–21 June 2009
Published: 11 August 2009
BMC Pharmacology 2009, 9(Suppl 1):S41 doi:10.1186/1471-2210-9-S1-S41
<supplement> <title> <p>4th International Conference of cGMP Generators, Effectors and Therapeutic Implications</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2210-9-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2210-9-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/9/S1/S41
© 2009 Thoonen et al; licensee BioMed Central Ltd. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pharmacology 2009, 9(Suppl 1):S41 http://www.biomedcentral.com/1471-2210/9/S1/S41
Page 2 of 2
(page number not for citation purposes)
esses in the body, such as the control of blood pressure
and heart rate, normal gastro-intestinal tract function and
development, and normal growth and viability.